ICON Public Limited Company (IJF) - Total Liabilities
Based on the latest financial reports, ICON Public Limited Company (IJF) has total liabilities worth €7.17 Billion EUR (≈ $8.39 Billion USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore investment intensity of ICON Public Limited Company to see how much of total assets are deployed in long-term investments.
ICON Public Limited Company - Total Liabilities Trend (2016–2024)
This chart illustrates how ICON Public Limited Company's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see ICON Public Limited Company assets under control.
ICON Public Limited Company Competitors by Total Liabilities
The table below lists competitors of ICON Public Limited Company ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
NEW ORIENTAL EDU.+TECH.G.
F:N1U0
|
Germany | €3.83 Billion |
|
Brown-Forman Corporation
NYSE:BF-B
|
USA | $3.87 Billion |
|
NMDC Limited
NSE:NMDC
|
India | Rs100.09 Billion |
|
INPOST S.A UNSP.ADR/1/2
F:6690
|
Germany | €14.24 Billion |
|
NISSAN MOTOR SP. ADR/2
F:NISE
|
Germany | €13.97 Trillion |
|
Telekom Malaysia Bhd
KLSE:4863
|
Malaysia | RM8.81 Billion |
|
Eastman Chemical Company
NYSE:EMN
|
USA | $9.14 Billion |
|
Yunnan Yuntianhua Co Ltd
SHG:600096
|
China | CN¥24.63 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down ICON Public Limited Company's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See ICON Public Limited Company balance sheet independence to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.77 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ICON Public Limited Company's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ICON Public Limited Company (2016–2024)
The table below shows the annual total liabilities of ICON Public Limited Company from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €7.35 Billion ≈ $8.60 Billion |
-5.09% |
| 2023-12-31 | €7.75 Billion ≈ $9.06 Billion |
-10.79% |
| 2022-12-31 | €8.69 Billion ≈ $10.16 Billion |
-6.80% |
| 2021-12-31 | €9.32 Billion ≈ $10.90 Billion |
+487.89% |
| 2020-12-31 | €1.59 Billion ≈ $1.85 Billion |
+22.95% |
| 2019-12-31 | €1.29 Billion ≈ $1.51 Billion |
+28.95% |
| 2018-12-31 | €999.97 Million ≈ $1.17 Billion |
+4.64% |
| 2017-12-31 | €955.62 Million ≈ $1.12 Billion |
+8.51% |
| 2016-12-31 | €880.67 Million ≈ $1.03 Billion |
-- |
About ICON Public Limited Company
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical stu… Read more